GLS and cancer: The chosen therapeutic strategy was based on the glutamine processing pathway in LUAD cells; wherein, we probed the ability of chemical inhibitors against glutaminase (CB‐839) and Psat1 (AOA) to modulate cancer cell growth by restricting the supply of α‐KG to the Krebs cycle (Fig 4A).